Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis

This publication has 21 references indexed in Scilit:

• A Novel Nonpsychotropic Cannabinoid, HU-211, in the Treatment of Experimental Pneumococcal Meningitis
  The Journal of Infectious Diseases, 1996
• HU-211, a Novel Noncompetitive N -Methyl- d- Aspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat
  Stroke, 1995
• Post-ischemic administration of HU-211, a novel non-competitive NMDA antagonist, protects against blood-brain barrier disruption in photochemical cortical infarction in rats: a quantitative study
  Brain Research, 1995
• Differential Inhibition of RAW264.7 Macrophage Tumoricidal Activity by 9Tetrahydrocannabinol
  Experimental Biology and Medicine, 1995
• Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist
  European Journal of Pharmacology, 1995
• Immunological Aspects of Experimental Allergic Encephalomyelitis and Multiple Sclerosis
  Critical Reviews in Clinical Laboratory Sciences, 1995
• Follow-up study of MS patients treated with high-dose intravenous methylprednisolone
  Acta Neurologica Scandinavica, 1994
• Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker.
  Proceedings of the National Academy of Sciences, 1989
• Δ9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis
  Journal of Neuroimmunology, 1989
• Enantiomeric cannabinoids: stereospecificity of psychotropic activity
  Cellular and Molecular Life Sciences, 1988